Silo Pharma Inc SILO 深 沪
等待开盘 07-02 09:30:00 美东时间
6.17
-0.040
-0.64%
华盛通- 最 高6.565
- 今 开6.04
- 成交量 6.59万股
- 最 低 6.00
- 昨 收 6.21
- 总市值 696.35万
- 52周最高 15.15
- 市盈率 静 --
- 换手率 5.84%
- 52周最低 3.315
- 委 比 81.82%
- 总股本 112.86万
- 历史最高 108.90
- 量 比 0.68
- 振 幅 9.10%
- 历史最低 3.315
- 每 手 1
- 风险率 2.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Silo Pharma Engages Drug-Device Development Partner Resyca To Carry Out Trial To Evaluate Nasal Spray System For Nose-To-Brain Delivery Of SPC-15 To Treat Post-Traumatic Stress Disorder
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced tha...
06-30 04:17
Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics an...
06-23 20:19
SILO Pharma Q1 EPS $(0.12) Up From $(0.23) YoY, Sales $18.026K, Same YoY
SILO Pharma (NASDAQ:SILO) reported quarterly losses of $(0.12) per share. This is a 47.83 percent increase over losses of $(0.23) per share from the same period last year. The company reported $18.026 thousand in sales
05-15 04:20
Silo Pharma Q1 FY26 net loss widens 59.7% to $1.65 million
Silo Pharma Q1 FY26 net loss widens 59.7% to $1.65 million Silo Pharma posted a wider net loss of USD 1.65 million, versus a 59.7% increase from the year-ago quarter, as operating loss widened 45.7% to USD 1.59 million. Revenue was flat at USD 18,026, while cost of revenues more than doubled to USD
05-14 18:05
Silo Pharma Launches Ibogaine-Based TBI Drug Initiative, Files Patent Amid Growing Psychedelic Therapy Push
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicinesSilo Pharma targets unmet need in a drug market with no FDA-approved therapies that
05-07 20:20
Silo Pharma highlights SPC-15 PTSD program after Trump order on psychedelic research
Silo Pharma highlights SPC-15 PTSD program after Trump order on psychedelic research Silo Pharma highlighted its PTSD drug program SPC-15 following President Trump executive order signed April 18, 2026 directing US agencies to accelerate psychedelic-therapy research and patient access. SPC-15 target
04-20 18:45
Silo Pharma Highlights Pipeline Strength Amid Rising U.S. Policy Focus On Psychedelic Mental Health Treatments.
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health TherapiesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), a developmental-stage
04-20 18:37
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Levi Strauss, Greenbrier And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures down, investors should watch Levi Strauss, Silo Pharma, Greenbrier, Mach Natural Resources, and Phoenix Education Partners.
04-07 15:21
Silo Pharma Secures European Patent Office Nod For Columbia‑Licensed Stress Therapy Using Serotonin 4 Receptor Agonists
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP PortfolioSARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the
04-07 04:19
